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Zusammenfassung
Epileptische Anfälle stellen in der pädiatrischen Onkologie ein
häufiges und klinisch relevantes Problem dar. Bedingt durch die
Heterogenität der betroffenen Patientengruppe und einer Viel-
zahl von möglichen Komorbiditäten sind sowohl das diagnos-
tische Vorgehen als auch die antikonvulsive Therapie eine be-
sondere Herausforderung, die ein interdisziplinäres Vorgehen
erfordert. Diagnostisch sind neben einer Vielzahl von potenziell
epileptogenen Medikamenten vor allem akute Begleiterkran-
kungen im Verlauf der Krebstherapie zu berücksichtigen, die ur-
sächlich für das Auftreten von Anfällen sein können. Beispiele
sind metabolische oder toxische Encephalopathien, ZNS-Infek-
tionen oder auch zerebrovaskuläre Ereignisse. Da diese zum Teil
lebensbedrohlichen Erkrankungen zum Teil kausal behandelbar
sind, erfordert jedes anfallsverdächtige Ereignisses eine rasche
und umfassende Abklärung. So können spezifische Ursachen er-
kannt und behandelt sowie unnötige antikonvulsive Langzeit-
therapien vermieden werden. Besteht eine Therapieindikation
zur antikonvulsiven Dauertherapie so liegt die Schwierigkeit pri-
mär in einer Vielzahl von Komedikationen und damit der Gefahr
von Wechselwirkungen insbesondere zwischen Antikonvulsiva
und Chemotherapeutika. Das Wissen um diese Wechselwirkun-
gen ist wichtig, da sowohl die Prognose der Krebserkrankung, als
auch die der Epilepsie hierdurch nennenswert beeinflusst wer-
den kann. Zusätzlich erschweren eine Reihe onkologisch rele-
vanter Nebenwirkungen die Entscheidungsfindung bei der Aus-
wahl der Antiepileptika. Dies betrifft z.B. kognitive Nebenwir-
kungen, myelotoxische Wirkungen, Dermatosen, endokrinolo-
Abstract
Epileptic seizures are a common and clinically relevant problem
in paediatric oncology. Attributable to the heterogeneity of this
group of patients and a number of possible comorbidities anti-
epileptic treatment in paediatric oncology poses a number of di-
agnostic and therapeutic challenges. This requires a close inter-
disciplinary approach to the seizing child or adolescent. A
prompt and detailed diagnostic work-up is needed in every case
in order to establish the diagnosis and, equally important, to de-
tect secondary aetiological factors, e.g. epileptogenic drugs or
any acute underlying pathology, such as metabolic or toxic ence-
phalopathies, CNS-infections or cerebrovascular events. This
might offer the opportunity for a specific causative treatment
and thus prevent unnecessary long-term antiepileptic drug
(AED) treatment. If AED treatment is initiated several aspects
have to be taken into account. Most importantly, AEDs and che-
motherapeutic drugs (CTDs) may interact. Depending on the co-
medication this may result in reduced tumour or seizure control
or unexpected toxicity of AEDs or CTDs. Understanding these in-
teractions will allow to anticipate clinically relevant adverse ef-
fects. AED may be further complicated by side-effects, some of
them of particular concern for children or adolescents, such as
cognitive effects, myelotoxicity, serious rashes, endocrinological
disturbances, and many more. Beside critically questioning the
need for AED treatment it is therefore important to prefer AED
with a good safety-profile in this population. Enzyme-inducing
and inhibiting AED should be avoided if possible. Preliminary
studies indicate that gabapentin and levetiracetam may provide
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Abbreviations
AED antiepileptic drug
ASP L-asparaginase
BBB blood brain barrier
BUS busulfan
CBZ carbamazepine
CIS cisplatin
CSA cyclosporine A
CTD chemotherapeutic drug
CYP cytochrome P 450
DNET dysembryoplastic neuroepithelial tumor
EIAED enzyme-inducing anti-epileptic drugs
ETX ethosuximide
IFO ifosfamide
MTX methotrexate
PBT phenobarbital
PHT phenytoin
TDM therapeutic drug monitoring
UGT UDP-glucoronosyltransferase
VPA valproic acid
Introduction
Seizures are a common complication in paediatric oncology and
often significantly impact the quality of life of patients and rela-
tives. This applies not only to children with brain tumours, where
an incidence of up to 70% depending on the type of tumour has
been reported [30], but also to systemic malignancies. A sizable
proportion of patients with systemic cancer present with at least
one seizure during the course of the disease. As an example, in
children and adolescents with acute lymphoblastic leukaemia a
seizure prevalence between 8 and 13% has been reported [45,
52, 76]. Aetiology includes a number of possibly preventable or
treatable conditions, which may be directly related to secondary
effects of anti-cancer treatment. Moreover, anticonvulsive drug
treatment in this particular group of patients comprises a num-
ber of difficulties, making seizures an interdisciplinary challenge.
Apart from the potential for serious side effects of antiepileptic
drugs (AEDs), some of them of particular concern for children, re-
cent years have seen new appreciation of drug interactions with
AEDs that are important in neoplastic disorders.
The current review aims to summarize some key aspects of antic-
onvulsive treatment in paediatric oncology.Wealso intend to criti-
cally question some current clinical policies and point out areas
suitable for future interdisciplinary research in this field.
Aetiology of seizures in paediatric oncology
The exact pathophysiology of seizures during the course of ma-
lignant diseases is often multifactorial and not well understood.
Seizures in patients with brain tumours are usually directly re-
lated to focal cerebral damages and effects on the surrounding
non-tumoural, cerebral tissue. This may be due to the tumour it-
self or to anti-cancer treatment (neurosurgery, irradiation, che-
motherapy). Etiological mechanisms include theories of altered
peritumoural amino acids, changes in regional metabolism in-
volving pH, neuronal or glial enzyme and protein expression,
and localized immunological changes. Distribution and function
of the NMDA subclass of glutamate receptors may also play a
role [3]. Certain tumours (e.g., oligodendroglioma, DNET, gang-
lioglioma) and tumour localisations appear to be associated
with a higher seizure risk (see Table 1 and 2). However, there is
some variation in seizure incidence even within a single histolo-
gical tumour subtype. Therefore, reliable risk factors are cur-
rently difficult to define particularly in the paediatric age group,
where only limited data are available [36].
gische Effekte und andere mehr. Neben der kritischen Indika-
tionsstellung einer antikonvulsiven Therapie gilt es daher bevor-
zugt Antikonvulsiva einzusetzen, die ein günstiges Nebenwir-
kungsprofil in dieser Patientengruppe haben und zusätzlich
durch fehlende Enzyminduktion bzw. Inhibition gekennzeichnet
sind. Nach aktuellem Kenntnisstand scheinen hier vor allem Ga-
bapentin und Levetiracetam günstige Optionen darzustellen. An-
gesichts einer sehr schlechten Studienlage sind jedoch weitere
klinische Studien zu diesen wichtigen Fragestellungen dringend
zu fordern, aktuelle Therapieregime kritisch zu hinterfragen und
gegebenenfalls der aktuellen Datenlage anzupassen.
Schlüsselwörter
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good options in terms of efficacy and safety. However, more
properly designed clinical studies are warranted to raise the lev-
el of evidence for robust clinical recommendations. Until that
time, clinicians will need to continue to question current policies
and adapt their daily practice to evolving scientific data.
Key words
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Table 1 Possible risk factors for seizure occurrence in patients with
brain tumours [69]
possible risk factors for seizures in brain tumours
lower-grade, slower growing tumours (epilepsy)
higher-grade rapidly progressive tumours (seizures at presentation)
superficial and cortical based tumours
parietal lobe and temporal lobe tumours
focal neurologic deficits
multifocal tumours
radiation therapy
incomplete tumour resection
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In systemic cancer the aetiology may be even more complex (see
Fig.1). Indirect effects of the cancer or its treatment such as brain
metastasis or leptomeningeal disease, hypertension, fever, CNS
infections, cerebral infarction or bleeding, electrolyte distur-
bances (hyponatraemia, hypocalaemia, hypomagnesaemia), me-
tabolic or toxic encephalopathies are possible reasons for epilep-
tic seizures. Chemotherapy and certain other drugs used for sup-
portive care in oncology are epileptogenic, especially in patients
with an altered blood-brain barrier (BBB) (see Table 3). These
secondary effects are often associated with the type and time-
course of the underlying malignancy, type of CTD, comedica-
tions, and acute illnesses related to tumour treatment. From the
clinical perspective it has to be stressed that a number of these
aetiological factors are treatable and/or preventable [17].
Seizures related to cancer treatment
In general, acute neurological symptoms under certain CTDs are
not uncommon [35, 55, 75]. The toxicity of CTDs to the central ner-
vous system is directly related to their ability to cross the BBB.
Clinical signs suggestive of neurotoxicity are usually non-specific:
altered level of consciousness, behavioural disorders and/or motor
deficits. Seizures are often part of the acute presentation [53].
The diagnosis of chemotherapy-induced seizures is made clini-
cally, and is based on the temporal relationship between drug
administration and neurological complication and, equally im-
portant, knowledge of side effects of specific agents. Therefore,
some clinically important CTDs associated with seizures are dis-
cussed in more detail.
Methotrexate (MTX)
MTX has the potential to cause both acute and delayed neuro-
toxicity, particularly after intrathecal (i. t.) or high dose intrave-
nous (i. v.) administration [52, 58] The mechanism of MTX-re-
lated neurotoxicity is still unclear. An excess of homocystein
and consecutively of excitatory neurotransmitters has been
found in some children [57]. Neurotoxicity usually manifests as
seizures, occurring a median of 10–11 days after i. t. MTX. The
frequency of seizures or other acute CNS effects during ALL ther-
apy in childhood has been reported at 3 to 13% [17, 45]. Neuro-
toxicity is usually self-limited and the risk of recurrence appears
to be low with re-treatment [55].
L-asparaginase (ASP)
ASP has been repeatedly related to cerebrovascular complica-
tions, which may be related to deficiencies of antithrombin III,
plasminogen, and fibrinogen [55]. In a recent case series Kieslich
et al. [38] reported five children with neurological complications
presenting with headache and seizures during the first three
weeks of ASP treatment. Three patients had venous thrombosis,
one presented a parenchymal haemorrhage.
A study of DiMario and Packer [17] found that almost half of the
seizures occurring in children with systemic cancers were attri-
butable to complications of ASP treatment. The epileptogenic ef-
fect of L-asparaginase may result from cleaving asparagine and
glutamine into aspartic acid, ammonia, and glutamate, an excita-
tory amino acid.
Ifosfamide (IFO)
Encephalopathy is a known adverse effect of IFO. The pathophy-
siology seems to be related to intoxication with chloracetalde-
hyde, a metabolic product of IFO [55]. The presentation and se-
verity varies greatly and involves a clinical spectrum ranging
from subclinical electroencephalographic changes, complicated
seizures to coma. Nonconvulsive status epilepticus has been de-
scribed in children and adults under IFO with reduced level of
consciousness [39, 56]. Onset of symptoms may be within hours
of administration without evidence of a dose-response curve. It
is generally self-limiting and reversible between 48 and 72 h after
discontinuation of IFO. However, severe and even fatal cases have
been reported [20]. Therefore, as effective therapy is available
especially for patients with severe symptoms of toxicity early di-
agnosis is essential (see Table 4; references [50, 54]. Whether re-
Fig. 1 Possible aetiological factors of seizures in oncological patients.
Table 3 Cancer treatment associated with seizure occurrence
(adopted from reference [55])
asparaginase, etoposide (IA), interleukin-2, busulphan (HD), erythropoietin,
levamisole, BCNU, 5-Fluorouracil, mechloramine, carboplatin (IA),
fludarabine, methotrexate, chorambucil (HD), GM-CSF, mitotane, cytosine
arabinoside (HD or IT), hexamethylmelamine, pentostatin, dacarbazine,
ifosfamide, thalidomide, interferon (IT), vinca alkaloids
HD: high-dose; IT: intra-thecal; IA: intra-arterial.
Table 2 Example of seizure incidence in paediatric brain tumours
(selected from reference [36])
tumor type seizure incidence (n = 157)
low-grade astrocytoma 19%
malignant astrocytoma 28%
medulloblastoma 8%
ependymoma 13%
PNET 25%
choroid plexus carcinoma 35%
optic pathway tumour 14%
germ cell 12%
pineoblastoma 23%
craniopharyngeoma 10%
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administration should be performed under prophylactic treat-
ment with methylen blue remains controversial. However, in
paediatric oncology, instead of re-administration replacement of
IFO by cyclophosphamide will usually be preferred.
Cisplatin (CIS)
CIS has principally been related to peripheral neurotoxicity.
However, CNS disorders such as the posterior reversible ence-
phalopathy syndrome (cortical blindness, hemiparesis, aphasia,
and coma) and isolated seizures have also been reported. CIS-re-
lated seizures may start within a few hours of the last CIS expo-
sure, and are not related to the cumulative CIS dose. Usually
these effects are completely reversible. Metabolic changes (e.g.
hypocalcaemia, hypomagnesaemia, and hyponatraemia) may
contribute to seizure susceptibility [75].
Busulfan (BUS)
BUS is a common component of conditioning regimens for haema-
topoietic stem cell transplantation. It rapidly crosses the BBB.
Neurotoxicity is a widely known complication of high-dose BU,
with seizures occurring in up to 7.5% of children without AED pro-
phylaxis [29]. Seizures may occur during BUS administration or
within 24 hours after the last dose, but seem to rarely happen be-
fore the seventh dose [16, 29]. It is now common practice to give
anticonvulsant prophylaxis along with high-dose BUS (see below).
Cyclosporine A (CSA)
Although not a classical CTD, CSA is often part of the therapeutic
regime in oncology. Neurotoxicity is one of the most significant
clinical side effects of the CSA, occurring in up to 60% of trans-
plant patients [66]. It is considered a drug with high epilepto-
genic potential [62]. However, the mechanism is poorly under-
stood. There might be some interference of CSA with mitochon-
drial energy metabolism [66]. Neurotoxicity may occur during
long-term treatment even when blood concentrations of CSA are
within the therapeutic range. Single seizures, status epilepticus
and development of the posterior reversible encephalopathy syn-
drome have frequently been published. Dose reduction or with-
drawal of CSA usually results in resolution of clinical symptoms.
Diagnostic approach after first seizure in paediatric oncology
Due to the complexity and variability of the paediatric oncologi-
cal population it is not possible to provide universal recommen-
dations how to approach seizures in these children. However,
some general aspects of the diagnostic work-up of a child after
a first seizure have to be considered.
Firstly, the importance of the correct diagnosis before initiation
of AED treatment cannot be overstated. There is a wide differen-
tial diagnosis of paroxysmal events in infancy and childhood and
misdiagnosis as epilepsy is common [35, 72] Conversely, more
subtle ictal events such as confusion, sensory or autonomic
symptoms might be misinterpreted as non-epileptic. Therefore,
the most important help to diagnosis is the clinical history sup-
ported by detailed seizure description from a witness to the epi-
sode [9]. Further information can sometimes be obtained from
an EEG. However, a normal interictal EEG does not exclude epi-
lepsy and vice versa. The gold standard for diagnosis would be
video-EEG-monitoring in order to document an ictal event. How-
ever, in clinical practice this is often not feasible. In patients with
reduced consciousness a non-convulsive status epilepticus has
to be strongly considered and early EEG should become a general
routine in such cases, particularly under certain CTDs, such as
IFO or MTX.
If a clear seizure has been documented it has to be differentiated
between a single seizure, which may be situation-related, and
epilepsy. Strong efforts have to be made to classify the patients
seizure, or less likely in oncology, place seizures in the context
of an epilepsy syndrome. Seizures may be febrile or non-febrile.
They might include a single symptom or have complex sympto-
matology. Description of seizures should be focused on precipi-
tating factors, the very initial ictal manifestations (aura? focal
onset?), and include the whole sequence of ictal symptoms as
well as postictal abnormalities. The initial symptomatology
may have localising value pointing to a specific seizure onset
zone [60]. Seizures may be generalised (e.g. absences, tonic-clo-
nic, myoclonic) or partial (focal onset) with or without second-
ary generalisation. Classification will often be essential for indi-
cation and selection of appropriate AEDs [27]. Brain tumour-re-
lated epileptic seizures are mostly focal, although generalization
is common and may occur so quickly that the focal phase re-
mains unnoticed. Generalized seizures are more common in
children with systemic malignancies. It can be assumed that
most seizures in oncology will be symptomatic. However, there
may be cases where a genetic seizure susceptibility is unmasked
by an acute illness and/or epileptogenic drugs.
Secondly, strong efforts have to be made to identify specific sec-
ondary effects that may have lead to increased seizure suscept-
ibility. In oncology some of these may even pose potentially life-
threatening conditions, such as CNS infections or cerebral bleed-
ings, intoxications or metabolic encephalopathies. Importantly,
causal treatment of the underlying condition may be possible in
a relevant proportion of patients. Therefore, an aggressive diag-
nostic work-up should be initiated promptly if a seizure occurs
during the course of a malignancy (see Fig. 2). Although cur-
rently not routinely performed, we propose to include detection
of drug levels of CTDs and/or their toxic metabolites (blood, CSF)
if possible. Toxic drug levels may be identified resulting in mod-
ification of therapy regimes. In addition, pooling these data with-
in clinical trials may enable clinicians to better understand the
pathophysiology of neurotoxicity of certain CTDs.
Treatment of seizures and epilepsy in paediatric oncology
In general, the clinical decision to initiate an AED is based on the
judgement that the risk of seizure occurrence outweighs the risk
Table 4 Methylene blue in IFO-encephalopathy [54]
methylene blue usual dose (i. v.) no. of daily doses
therapeutic 50mg 6 (until symptoms recede)
preventive 50mg 4
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of AEDs and their possible toxic effects [21]. Predicting the risk of
seizure recurrence forms another essential part of the decision for
or against AED treatment. However, this may be particularly diffi-
cult in paediatric oncology. In general, seizure recurrence in chil-
dren who suffered the first seizure during the intensive CTD treat-
ment phase tends to be infrequent, usually occurring within three
to six months of the first seizure. Often, AED may be discontinued
shortly after the causative abnormality has been corrected, thus
preventing unnecessary initiation of long-term AED treatment
[30, 37]. Options may be treatment of CNS infections, correction
of electrolyte disturbances including the critical review of the cur-
rent hydration regime and/or diuretic treatment, correction of
blood sugar, discontinuation of potentially causal CTD, and, if
available, antagonistic treatment (e.g. IFO). If a CTD is likely causal
for seizure occurrence its indication, dosage, and infusion rate
should be critically questioned. In addition, the patient should be
immediately reported to the clinical trial office. Alternative treat-
ment should be considered before re-exposure for those patients
who developed seizures attributable to a certain CTD.
However, the recurrence risk may be significantly higher in chil-
dren with fixed neurological abnormalities and certain cerebral
defects [45]. In adults with brain tumours it appeared that the
earlier seizures occurred in the course of illness, the more likely
they are to recur [69]. Brain imaging might sometimes offer im-
portant information contributing to the treatment decision.
If initiation of AED treatment is indicated, the choice of AED in
paediatric oncology is based on the classification of seizures,
age and sex of the patient, comorbidities, and comedications.
An individualized approach is therefore required in any such
case. We strongly suggest that a paediatrician with expertise in
epilepsies in children should always be involved in this complex
decision process, the regular review of antiepileptic manage-
ment and withdrawal of treatment.
Drug interactions in paediatric oncology
A main challenge of AED treatment in paediatric oncology is the
high number of comedications to be expected in the majority of
patients [43, 74]. This will inevitably imply the potential for
pharmacokinetic and pharmacodynamic drug interactions and
it may be almost impossible to predict every pharmacological
modification caused by the variety of drugs given at the same
time. Pharmacokinetic drug interactions may result in changes
of absorption, elimination, protein binding, or distribution of a
drug. Drug metabolism accounts for most clinically relevant
pharmacokinetic drug interactions between AEDs and CTDs, par-
ticularly those involving cytochrome P450 (CYP) isoenzymes in
hepatic metabolism. Many of the drugs in use in paediatric on-
cology are metabolised by the CYP isoenzyme system and thus
interactions mainly derive from inhibition or induction of these
isoenzymes. The main isoenzymes in AED metabolism are
CYP3A4, CYP2C9, and CYP2C19. For CTD metabolism, CYP3A4 is
the most important. In addition, UDP-glucoronosyltransferase
(UGT) enzymes can also play a role. The potential of enzyme in-
duction and inhibition varies widely among AED (see Table 5).
Fig. 2 Suggested diagnostic work up after a
seizure in the oncological child.
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According to the systematic approach by Vecht et al. [74] the most
relevant clinical consequences of drug interactions or altered
pharmacodynamics, respectively, can be summarized as follows:
a) reduced efficacy of antiepileptic drugs, b) reduced efficacy of
CTD, c) increased toxicity of AED, d) increased toxicity of CTD.
Although only very few clinical studies have focussed on these
special issues, case reports provide alarming evidence that this
is by no means only a theoretical matter, but has strong impact
on clinical routine and decision making. This is illustrated by
some exemplary data provided by current literature.
Reduced efficacy of antiepileptic drugs
A number of case-reports of adult patients demonstrated a
marked drop of phenytoin (PHT) concentrations of up to 50%
after CTD administration. This was mainly attributed to cisplatin
[22]. In a retrospective study by Grossmann et al. [26] all pa-
tients who received three or more cycles of cisplatin and car-
mustine chemotherapy for primary brain tumours required an
average increase in their maintenance PHT dose of 41% to
achieve therapeutic PHT levels.
Valproic acid (VPA) has also been reported to be influenced by
cisplatin. In a patient receiving daily VPA, severe seizures were
observed 7weeks after the first cisplatin-based chemotherapy
cycle, when the serum VPA concentration was found to be re-
duced by approximately 50% of the initial level [32]. Another
case report described the recurrence of tonic-clonic seizure in a
child with acute lymphoblastic leukaemia under VPA therapy a
few hours after high-dose MTX. An acute decline of the serum
VPA concentration to about 25% of the pre-MTX value could be
observed [64].
Reduced efficacy of CTD
The potential of drug interactions to significantly worsen the
outcome of malignant diseases under CTD was impressively illu-
strated by a study of Relling et al. [59]. Forty of 716 (5.6%) conse-
cutive children treated for acute lymphoblastic leukaemia re-
ceived treatment for 30 days or longer with enzyme-inducing
anticonvulsants (PHT, PBT, CBZ, or a combination) at the same
time as antileukaemic therapy. In this study anticonvulsant ther-
apy was significantly related to worse event-free survival with
occurrence of more haematological, and CNS relapses among
the 566 patients with B-lineage leukaemia. A faster clearance of
teniposide and methotrexate was found among patients receiv-
ing AEDs [59].
A very recent retrospective study by Oberndorfer et al. [51] eval-
uated the effects of coadministration of AED on survival rates of
patients with glioblastomamultiforme, who underwent surgery,
radiotherapy and chemotherapy. A significant decline of survival
rates in the group of patients who received enzyme-inducing
AEDs (EIAED) was found.
Another clinically important example refers to data provided
from Hassan et al. [29] who were first to systematically study
the influence of PHT as preventative AED on BUS pharmacoki-
netics and pharamcodynamics in patients during conditioning
prior to bone marrow transplantation using BUS. They reported
a significantly faster clearance, a lower area under the concen-
tration-time curve and a shorter half-life if the BUS regime was
combined with PHT.
Increased toxicity of AED
Very little data are available on this possible effect of interaction.
Fluorouracil, an inhibitor of the CPY2C9 isoezyme, has been re-
ported to induce toxic plasma concentrations of PHT leading to
severe neurological deficits mainly attributed to cerebellar dis-
turbances (Brickel et al. 2003). It can be speculated that in-
creased toxicity of AEDs under certain enzyme-inhibiting CTDs
is underrepresented in current literature.
Increased toxicity of CTD
VPA is a potent inhibitor of the CYP isoenzymes, mainly of CYP2C9.
As VPA has very recently been studied as an adjunctive therapy for
acute myeloid leukaemia and myelodysplastic syndrome [10], in-
teractions with certain CTDs might become more relevant in fu-
ture. In a follow-up study of 70 adults with high-grade gliomas
an association of VPA with a fotemustine-cisplatin regimen re-
sulted in a three-fold higher incidence of reversible thrombopenia,
neutropenia or both. Haematological side-effects decreased after
AED modification during the continued chemotherapy [7].
Increased toxicity of IFO has been reported in a paediatric patient
who received PBT as comedication. He developed IFO-encephalo-
pathy, which was attributed to the enzyme inducing activity of
PBT leading to a higher amount of toxic IFO-metabolites [23].
Corticosteroids und AED
Interactions between corticosteroids and PHTand/or PBTmay be
almost unpredictable. A variety of effects have been observed.
PHT and PBT have the potential to shorten the half-life and in-
crease total body clearance of dexamethasone and prednisone
[11]. On the other hand, both increased and lowered levels of
PHT were seen under comedication with dexamethasone. Lack-
ner [40] reported a patient receiving dexamethasone who re-
quired a daily PHT dose of greater than 10mg/kg to maintain
Table 5 Enzyme-inducing or inhibiting characteristics of different
AED
AED inducer inhibitor
carbamazepine yes (CYP3A4, CYP2C19, CYP2C19) no
clobazam no no
ethosuximide no no
gabapentin no no
lamotrigine yes (UGT) no
levetiracetam no no
oxcarbazepine yes (CYP3A4 UGT) yes (CYP2C19)
phenobarbital yes (CYP3A4, CYP2C19, CYP2C19) no
phenytoin yes (CYP3A4, CYP2C19, CYP2C19) no
pregabaline no no
sulthiame no yes (CYP2C)
tiagabine no no
topiramate yes (CYP3A4) yes (CYP2C19)
valproic acid no yes (CYP2C9)
zonisamide no no
R
eview
A
rticle
345
Tibussek D et al. Antiepileptic Treatment in… Klin Pädiatr 2006; 218: 340–349
therapeutic serum concentration. The concentration increased
by nearly 300% after dexamethasone was discontinued. Con-
trary, Lawson et al. [42] reported increased levels of PHT in pa-
tients receiving PHT and dexamethasone. This may be attributed
to competition on protein binding leading to intoxications,
which also might mimic tumour progression. It has been hy-
pothesized that decreased levels may be caused by induction of
hepatic metabolism causing a loss of seizure control [61]. How-
ever, the real pathophysiology of these contradictory effects is
poorly understood.
Summarizing these results it can be stated that drug interactions
between AEDs and CTDs can have substantial effects on clinical
outcome. We therefore propose that therapeutic drug monitor-
ing may contribute to improving cancer chemotherapy and
should therefore be further investigated particularly in view of
a variety of possible drug interactions between AEDs and CTDs.
Adverse effects of AED relevant in paediatric oncology
Newer and more aggressive treatments of malignancies in child-
hood have lead to significantly longer survival rates of affected
children. Therefore, adverse effects of long-term anticonvulsive
treatment have to be considered. It is beyond the scope of this
review to cover all these aspects of AED treatment in detail. A
summary of the most relevant side effects of frequently used
AED in paediatrics is given in Table 6. Some aspects are of special
relevance in paediatric oncology.
AED related haematological side effects are particularly un-
wanted in paediatric oncology. Although the overall incidence
in non-oncological patients seems to be low [6], it has been re-
ported that, when AEDs are used in combination with antineo-
plastic agents, these effects can be pronounced [7]. Aplastic
anaemia (CBZ, PBT, PHT, ETX) and thrombopenia (VPA) are most
commonly reported.
Serious rashes, including Stevens-Johnson syndrome and anti-
convulsant hypersensitivity syndrome are rare, but potentially
fatal adverse effects that can occur and are more common when
certain AEDs (PHT, PBT, CBZ) are used in combination with irra-
diation therapy [47].
One of the most severe long-term sequelae of childhood cancer
treatment may be neurocognitive disorders [4]. In this context
CNS side-effects of AEDs are particularly worrying. No AED ap-
pears to be completely exempt from unfavourable cognitive
and/or behavioural effects [2]. Previous clinical studies indicate
that older AEDs have the most negative cognitive profile, mainly
PB and PHT [18, 49]. However, even the “new” AEDs, e.g., topira-
mate or levetiracetam, have been associated with adverse cogni-
tive or neurobehavioral effects. Lamotrigine seems to have a fa-
vourable cognitive profile [1, 46, 67].
Appetite regulation can be a relevant clinical problem in oncol-
ogy in both terms, uncontrolled eating, mainly in cerebral malig-
nancies or anorexia, either due to CTDs or the malignancy itself.
These effects may be worsen by certain AED (see Table 6).
Table 6 Commonly prescribed AED in childhood, dosage, side-effects [2, 5, 13, 27]
AED usual oral dosage mg/
kg per day
neurobehavioral/cognitive
changes
weight changes inducing estrogen
metabolism
further important/serious side-effects
carbamazepine 10–20 + (memory impairment) weight gain ++ rash, aplastic anaemia (rare), ataxia,
diplopia
clobazam 0.5–1 + (sedation) weight neutral – hypersecretion, development
of tolerance
ethosuximide 20–30 rare (psychosis) weight loss – aplastic anaemia (rare), rash, hiccups
gabapentin 23–35 + (behavioral problems) weight gain –
lamotrigine slow titration depending
on comedication*
± (Insomnia) weight neutral + rash, including Stevens-Johnsons
syndrome, diplopia, ataxia
levetiracetam 20–40 + (behavioral problems;
psychotic events)
weight loss? – salivary hypersecretion
oxcarbazepine 30–45 – weight gain + hyponatriaemia, rash, ataxia
phenobarbital 2–5 ++ (cognitive and sedative
effects)
weight neutral ++ aplastic anaemia
phenytoin 8–10 <3 years
4–7 >3 years
++ (cognitive and sedative
effects)
weight neutral ++ aplastic anaemia, cerebellar toxicity,
cardiac arrythmia, purple glove syn-
drome
sulthiame 5–15 rare (psychotic events) weight loss – ataxia, paresthesia, tachypnoea
topiramate slow titration: 4–6 + (language impairment) weight loss + nephrolithiasis, glaucoma, hypohydro-
sis, metabolic acidosis
valproic acid 15–40 ± (hyperactivity) weight gain – thrombopenia, hepatic failure, hyper-
ammonemia, pancreatic failure, tre-
mor
zonisamide 4–12 ++ (psychiatric disorders) weight loss – rash, ataxia, hypohydrosis
*add-on enzyme-inducers: 5–15mg/kg; add-on VPA: 1–3mg/kg
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Effects of long-term AED treatment on hormonal function, con-
traception, sexuality, and pregnancy is an important issue for
adolescents [33]. Early counselling on effective contraception is
essential in female teenagers with cancer in order to prevent un-
wanted pregnancies particularly in view of potentially terato-
genic andmutagenic drugs during cancer treatment [41]. The in-
fluence of AED selection on current or future choices of contra-
ceptive methods needs to be considered when choosing an AED
for those patients who are likely to continue treatment into their
childbearing years. Nonenzyme-inducing AEDs do not show any
interactions with the oral contraceptive pill and should therefore
be preferred in these patients [14, 78]. Reduced fertility in wom-
en with epilepsy and foetal damages due to AEDs used during
pregnancy are additional concerns [71].
Choice of AED in paediatric oncology
The primary concern of AED treatment is maintaining adequate
seizure control. Although exact epidemiological data are missing
it can be presumed that themajority of seizures in paediatric on-
cology will be partial or secondary generalized. A variety of older
and newer AED have been shown good effectiveness in children
with focal epilepsy [27]. However, the use of enzyme-inducing
AED as drugs of first choice is still wide routine in paediatric on-
cology departments, mainly PHT, PBT, and CBZ. VPA has also
been recommended [30]. However, having inmind the above de-
scribed potentially fatal effects of drug interactions between
AED and CTD it seems reasonable to propose that AEDs not in-
ducing or inhibiting the cytochrome P450 system should be pre-
ferred. As rapid titration is often required, gabapentin or levetir-
acetam have been suggested as possible candidates with good
efficacy and a favourable safety profile [34, 36, 74]. Gabapentin
has been proven effective in partial seizures [19]. There is some
experience that gabapentin is well tolerated and provide effec-
tive seizure control in children under CTD [36]. Levetiracetam is
considered as a wide-spectrum AED effective in both partial and
generalized seizures [19, 63]. In adults with end stage brain tu-
mours levetiracetam has been reported as a good option due to
its efficacy and tolerability [34]. In children with treatment-re-
sistant partial seizures it was effective and well tolerated as ad-
junctive therapy [25].
However, it has to be stressed that recommendations of long-
term AED treatment in the oncology patient are not supported
by robust empirical evidence. In addition, due to the complexity
of patients under cancer treatment an individualized approach
to any such child with epilepsy is required. According to the spe-
cific patients needs different AED treatment regimes may be in-
dicated, including enzyme-inducing AED or combination ther-
apy. Therefore, the right choice of treatment requires consider-
able expertise in the care of paediatric epilepsy patients.
If only short-term use is expected, clonazepan may be a candidate
with an excellent broad-spectrum efficacy. Its use is sometimes
limited by sedating effects, hypersalivation, ataxia, and most im-
portantly, the development of tolerance, usually after 3–6months.
Short-term use of PHT, PB or VPA may be justified if i.v.-applica-
tion is necessary. However, closed monitoring of drug levels of
CTDs and AEDs is essential. If possible, therapy should rapidly
be changed to non-enzyme inducing or inhibiting AED once the
patient’s status has stabilized. It needs to be stressed that this
may again lead to significant alterations of CTD levels.
Patients with progressive tumours or severe mucositis might lose
the ability to swallow even suspensions. Beside i.v.- and i.m.-
preparations (e.g. PB; [34]), buccal application might be consid-
ered on this occasion. This is an option for lorazepam and mida-
zolam. Sedative side-effects of these AED may even be desirable.
In addition, lorazepam has antiemetic and anxiolytic properties.
As mentioned above, epilepsy treatment in female teenagers
pose a number of additional difficulties. Treatment decisions
should follow currently existing guidelines for the management
of epilepsy in women (e.g. [14]).
Different regimens have been suggested as preventative AED
treatment in patients undergoing high-dose busulfan therapy
(see Table 7). PHT should no longer be used for its potential for
drug interaction and a unfavourable profile of adverse effects [29].
Last but not least it is noteworthy to mention that especially in
brain tumour patients seizures may be refractory to medical man-
agement and epilepsy surgery can sometimes be performed [69].
Seizure prophylaxis in children with brain tumours
Because a substantial number of patients with brain tumours may
develop seizures, it remains common practice among neurooncol-
ogists and neurosurgeons to initiate preventive AED treatment
even in the absence of seizures. Many patients who have experi-
enced a single seizure attributable to brain tumours will be put
on regular AED and often keep on taking their anticonvulsive
medication for years. The rational for this policy has been ad-
dressed in several studies, but continues to be controversial [68].
However, growing evidence clearly points against the usefulness
of preventive AED treatment. A practice parameter established by
the American Academy of Neurology [24] recommended that pro-
phylactic anticonvulsants should not be used routinely in patients
with newly diagnosed brain tumours. Perioperative prophylaxis
should be tapered off after the first postoperative week. In support
of this view, two recent meta-analyses found no evidence to sup-
port AED prophylaxis with PBT, PHT, or valproic acid in patients
with brain tumours and no history of seizures, regardless of neo-
plastic type [68, 70]. However, currently available data need to be
interpreted with some caution. None of the studies included in
Table 7 Busulfan and options of preventive AED treatment
AED dosage reference
clonazepan 0.1mg/kg/d as a continous
i. v. infusion
Vassal et al. 1990 [73]
clobazam 0.05mg/kg twice a day by
mouth
Schwarer et al. 1995 [65]
lorazepam 0.02 (infants <2 yrs)–0.05mg/
kg i. v. or p.o. every 6 h
Chan et al. 2002 [12]
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meta-analyses were performed using newer AED. Moreover, there
is a lack of reliable risk-factors predictive for seizure occurrence
in children with cerebral tumours.
In addition, it needs to be stressed, that once a patient experi-
ences a seizure clearly attributable to a brain tumor, long-term
treatment with AED is generally accepted as proper medical
care due to the high risk of recurrence [69].
Conclusion
Antiepileptic treatment in paediatric oncology poses numerous
diagnostic and therapeutic challenges. This requires a close in-
terdisciplinary approach to the seizing child or adolescent. A
prompt and detailed diagnostic work-up is needed in every sin-
gle case in order to establish the diagnosis and, equally impor-
tant, to detect any treatable underlying pathology.
If clinical events are not clearly defined as seizures the best way
to prevent adverse effects of AEDs is to consider not to give AED
at all. Preventive AED treatment in patients with primary brain
tumours cannot be recommended.
If AED treatment is initiated possible drug interactions and side
effects relevant in paediatric oncology have to be taken into ac-
count. Enzyme inducing and inhibiting AEDs should be avoided
unless alternative treatment with non-inducing AEDs is not fea-
sible. Regular review of the continuing need for AED treatment is
always required.
Regarding the new non-enzyme inducing or inhibiting AEDs,
preliminary studies indicate that gabapentin and levetiracetam
may provide a favourable profile in terms of efficacy and safety.
However, more properly designed clinical studies are warranted
to raise the level of evidence for robust clinical recommenda-
tions. These studies should also investigate the influence of AED
treatment on overall outcomemeasures. We believe that compe-
tence networks will be helpful to structure clinical trials and
standardize future therapy regimes [15]. Clinicians will need to
continue to question current policies and adapt their daily prac-
tice to evolving scientific data.
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